Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy.


Journal

Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 13 06 2023
accepted: 01 02 2024
medline: 8 3 2024
pubmed: 8 3 2024
entrez: 7 3 2024
Statut: aheadofprint

Résumé

The identification of patient-derived, tumor-reactive T cell receptors (TCRs) as a basis for personalized transgenic T cell therapies remains a time- and cost-intensive endeavor. Current approaches to identify tumor-reactive TCRs analyze tumor mutations to predict T cell activating (neo)antigens and use these to either enrich tumor infiltrating lymphocyte (TIL) cultures or validate individual TCRs for transgenic autologous therapies. Here we combined high-throughput TCR cloning and reactivity validation to train predicTCR, a machine learning classifier that identifies individual tumor-reactive TILs in an antigen-agnostic manner based on single-TIL RNA sequencing. PredicTCR identifies tumor-reactive TCRs in TILs from diverse cancers better than previous gene set enrichment-based approaches, increasing specificity and sensitivity (geometric mean) from 0.38 to 0.74. By predicting tumor-reactive TCRs in a matter of days, TCR clonotypes can be prioritized to accelerate the manufacture of personalized T cell therapies.

Identifiants

pubmed: 38454173
doi: 10.1038/s41587-024-02161-y
pii: 10.1038/s41587-024-02161-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 404521405
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 259332240

Informations de copyright

© 2024. The Author(s).

Références

Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
pubmed: 36477031 doi: 10.1056/NEJMoa2210233
Monberg, T. J., Borch, T. H., Svane, I. M. & Donia, M. TIL therapy: facts and hopes. Clin. Cancer Res. 29, 3275–3283 (2023).
pubmed: 37058256 doi: 10.1158/1078-0432.CCR-22-2428
Cohen, C. J. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125, 3981–3991 (2015).
pubmed: 26389673 doi: 10.1172/JCI82416 pmcid: 4607110
Crompton, J. G., Sukumar, M. & Restifo, N. P. Uncoupling T cell expansion from effector differentiation in cell-based immunotherapy. Immunol. Rev. 257, 264–276 (2014).
pubmed: 24329803 doi: 10.1111/imr.12135 pmcid: 3915736
Poschke, I. C. et al. The outcome of ex vivo TIL expansion is highly influenced by spatial heterogeneity of the tumor T cell repertoire and differences in intrinsic in vitro growth capacity between T cell clones. Clin. Cancer Res. 26, 4289–4301 (2020).
pubmed: 32303540 doi: 10.1158/1078-0432.CCR-19-3845
Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724–730 (2018).
pubmed: 29867227 doi: 10.1038/s41591-018-0040-8 pmcid: 6348479
Wang, B. et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat. Biomed. Eng. 5, 429–440 (2021).
pubmed: 34002062 doi: 10.1038/s41551-021-00730-z
Simoni, Y. et al. Bystander CD8
pubmed: 29769722 doi: 10.1038/s41586-018-0130-2
Hundal, J. et al. PVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol. Res. 8, 409–420 (2020).
pubmed: 31907209 doi: 10.1158/2326-6066.CIR-19-0401 pmcid: 7056579
Shah, N. M. et al. Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. Nat. Genet. 55, 631–639 (2023).
pubmed: 36973455 doi: 10.1038/s41588-023-01349-3
Bartok, O. et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature 590, 332–337 (2021).
pubmed: 33328638 doi: 10.1038/s41586-020-03054-1
Kacen, A. et al. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat. Biotechnol. 41, 239–251 (2023).
pubmed: 36203013 doi: 10.1038/s41587-022-01464-2
Ouspenskaia, T. et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat. Biotechnol. 40, 209–217 (2022).
pubmed: 34663921 doi: 10.1038/s41587-021-01021-3
Naghavian, R. et al. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature 617, 807–817 (2023).
pubmed: 37198490 doi: 10.1038/s41586-023-06081-w pmcid: 10208956
Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463–468 (2021).
pubmed: 33762734 doi: 10.1038/s41586-021-03363-z pmcid: 8046668
Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8
pubmed: 34290406 doi: 10.1038/s41586-021-03704-y pmcid: 9187974
Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4
pubmed: 35508657 doi: 10.1038/s41586-022-04682-5 pmcid: 9815755
Veatch, J. R. et al. Neoantigen-specific CD4
pubmed: 35413271 doi: 10.1016/j.ccell.2022.03.006 pmcid: 9011147
Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126–132 (2021).
Hanada, K. et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40, 479–493.e6 (2022).
pubmed: 35452604 doi: 10.1016/j.ccell.2022.03.012 pmcid: 9196205
Zheng, C. et al. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell 40, 410–423.e7 (2022).
pubmed: 35413272 doi: 10.1016/j.ccell.2022.03.005
Meng, Z. et al. Transcriptome-based identification of tumor-reactive and bystander CD8
doi: 10.1126/scitranslmed.adh9562
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).
pubmed: 35113651 doi: 10.1126/science.abl5447 pmcid: 8996692
Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 25, 1549–1559 (2019).
pubmed: 31591606 doi: 10.1038/s41591-019-0592-2 pmcid: 6890490
Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).
pubmed: 32424352 doi: 10.1038/s41588-020-0628-z pmcid: 7343625
Chen, T. & Guestrin, C. XGBoost: a scalable tree boosting system. Proc. 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 785–794 (ACM, 2016).
Lundberg, S. M. & Lee, S.-I. in Advances in Neural Information Processing Systems Vol. 30 (eds Guyon, I. et al.) (Curran Associates, 2017).
Yoshida, M. et al. Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature 602, 321–327 (2022).
pubmed: 34937051 doi: 10.1038/s41586-021-04345-x
Picelli, S. et al. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat. Methods 10, 1096–1100 (2013).
pubmed: 24056875 doi: 10.1038/nmeth.2639
Shugay, M. et al. VDJdb: a curated database of T cell receptor sequences with known antigen specificity. Nucleic Acids Res. 129, 170–177 (2017).
Ahlmann-Eltze, C. & Huber, W. Comparison of transformations for single-cell RNA-seq data. Nat. Methods 20, 665–672 (2023).
pubmed: 37037999 doi: 10.1038/s41592-023-01814-1 pmcid: 10172138
Yu, L., Cao, Y., Yang, J. Y. H. & Yang, P. Benchmarking clustering algorithms on estimating the number of cell types from single-cell RNA-sequencing data. Genome Biol. 23, 49 (2022).
pubmed: 35135612 doi: 10.1186/s13059-022-02622-0 pmcid: 8822786
Wang, Z. et al. Identification and verification of immune subtype-related lncRNAs in clear cell renal cell carcinoma. Front. Oncol. 12, 369–373 (2022).
Song, G. Y. et al. Differential expression profiles and functional analysis of long non-coding RNAs in calcific aortic valve disease. BMC Cardiovasc. Disord. 23, 1–13 (2023).
doi: 10.1186/s12872-023-03311-x
Wu, W. et al. Tissue-specific co-expression of long non-coding and coding RNAs associated with breast cancer. Sci. Rep. 6, 1–13 (2016).
Pogorelyy, M. V. et al. Detecting T cell receptors involved in immune responses from single repertoire snapshots. PLoS Biol. 17, 1–13 (2019).
doi: 10.1371/journal.pbio.3000314
Schmidt, J. et al. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat. Commun. 14, 3188 (2023).
pubmed: 37280206 doi: 10.1038/s41467-023-38946-z pmcid: 10244384
Schmid, T. et al. T-FINDER: a highly sensitive, pan-HLA platform for functional T cell receptor and ligand discovery. Sci. Adv. 10, adk3060 (2024).
Grigoriadis, K. et al. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction. Protoc. Exch. 562, 833–845 (2023).
Jokinen, E. et al. TCRconv: predicting recognition between T cell receptors and epitopes using contextualized motifs. Bioinformatics 39, btac788 (2023).
pubmed: 36477794 doi: 10.1093/bioinformatics/btac788
Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
doi: 10.1038/s41586-020-1969-6
Reisinger, E. et al. OTP: an automatized system for managing and processing NGS data. J. Biotechnol. 261, 53–62 (2017).
pubmed: 28803971 doi: 10.1016/j.jbiotec.2017.08.006
Orenbuch, R. et al. ArcasHLA: high-resolution HLA typing from RNAseq. Bioinformatics 36, 33–40 (2020).
pubmed: 31173059 doi: 10.1093/bioinformatics/btz474
Song, L. et al. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. Nat. Methods 18, 627–630 (2021).
pubmed: 33986545 doi: 10.1038/s41592-021-01142-2 pmcid: 9328942
Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4, 1686 (2019).
doi: 10.21105/joss.01686
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Enhanced antitumor activity of murine–human hybrid T cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878–8886 (2006).
pubmed: 16951205 doi: 10.1158/0008-5472.CAN-06-1450 pmcid: 2147082
Cohen, C. J. et al. Enhanced antitumor activity of T cells engineered to express T cell receptors with a second disulfide bond. Cancer Res. 67, 3898–3903 (2007).
pubmed: 17440104 doi: 10.1158/0008-5472.CAN-06-3986 pmcid: 2147081
Bozza, M. et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci. Adv. 7, eabf1333 (2021).
pubmed: 33853779 doi: 10.1126/sciadv.abf1333 pmcid: 8046366
Bocchi, M. et al. Inverted open microwells for cell trapping, cell aggregate formation and parallel recovery of live cells. Lab Chip 12, 3168–3176 (2012).
Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. Lecture Notes in Computer Science Vol. 11071 (Springer, 2018).
Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
pubmed: 28091601 doi: 10.1038/ncomms14049 pmcid: 5241818
R: A Language and Environment for Statistical Computing (R Core Team, 2022).
Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9, giaa151 (2020).
pubmed: 33367645 doi: 10.1093/gigascience/giaa151 pmcid: 7763177
Hippen, A. A. et al. miQC: an adaptive probabilistic framework for quality control of single-cell RNA-sequencing data. PLoS Comput. Biol. 17, e1009290 (2021).
pubmed: 34428202 doi: 10.1371/journal.pcbi.1009290 pmcid: 8415599
Human T cells from a healthy donor, 1k cells – multi (v2). 10X Genomics https://www.10xgenomics.com/datasets/human-t-cells-from-a-healthy-donor-1-k-cells-multi-v-2-2-standard-5-0-0 (2020).
Szabo, P. A. et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat. Commun. 10, 4706 (2019).
pubmed: 31624246 doi: 10.1038/s41467-019-12464-3 pmcid: 6797728
Gao, S. et al. Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells. Nat. Commun. 13, 1982 (2022).
pubmed: 35411048 doi: 10.1038/s41467-022-29175-x pmcid: 9001664
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).
pubmed: 34062119 doi: 10.1016/j.cell.2021.04.048 pmcid: 8238499
Head, T. et al. scikit-optimize/scikit-optimize (v0.9.0). Zenodo https://doi.org/10.5281/zenodo.5565057 (2021).
Andreatta, M. & Carmona, S. J. UCell: robust and scalable single-cell gene signature scoring. Comput. Struct. Biotechnol. J. 19, 3796–3798 (2021).
pubmed: 34285779 doi: 10.1016/j.csbj.2021.06.043 pmcid: 8271111
Berset, M. et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int. J. Cancer 95, 73–77 (2001).
pubmed: 11241315 doi: 10.1002/1097-0215(20010120)95:1<73::AID-IJC1013>3.0.CO;2-S

Auteurs

C L Tan (CL)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.
Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

K Lindner (K)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.
Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany.
Immune Monitoring Unit, National Center for Tumor Diseases, Heidelberg, Germany.

T Boschert (T)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.
Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Helmholtz Institute for Translational Oncology, Mainz, Germany.

Z Meng (Z)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.
Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

A Rodriguez Ehrenfried (A)

Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Helmholtz Institute for Translational Oncology, Mainz, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

A De Roia (A)

Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
DNA Vector Laboratory, German Cancer Research Center, Heidelberg, Germany.

G Haltenhof (G)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.
Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany.

A Faenza (A)

Cellply Srl, Bologna, Italy.

F Imperatore (F)

Cellply Srl, Bologna, Italy.

L Bunse (L)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.
Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany.

J M Lindner (JM)

BioMed X GmbH, Heidelberg, Germany.

R P Harbottle (RP)

DNA Vector Laboratory, German Cancer Research Center, Heidelberg, Germany.

M Ratliff (M)

Department of Neurosurgery, University Hospital Mannheim, Mannheim, Germany.

R Offringa (R)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.
Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

I Poschke (I)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.
Immune Monitoring Unit, National Center for Tumor Diseases, Heidelberg, Germany.

M Platten (M)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany. m.platten@dkfz.de.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany. m.platten@dkfz.de.
Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany. m.platten@dkfz.de.
Immune Monitoring Unit, National Center for Tumor Diseases, Heidelberg, Germany. m.platten@dkfz.de.
Helmholtz Institute for Translational Oncology, Mainz, Germany. m.platten@dkfz.de.
German Cancer Research Center-Hector Cancer Institute at the Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. m.platten@dkfz.de.

E W Green (EW)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany. e.green@dkfz.de.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany. e.green@dkfz.de.
Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany. e.green@dkfz.de.

Classifications MeSH